SAGED

Our goal is to empower healthcare professionals with the knowledge to integrate medical cannabis into their practice confidently. Explore our latest releases and enhance your understanding of medical cannabis in clinical practice at www.saged.com.au 🌿 #healthcareeducation #MedicalCannabis #HealthcareProfessionals

🔍 Clinical Case Study: Managing HIV Symptoms with Medical Cannabis Meet Peter, a 45-year-old managing HIV. Anxiety and insomnia from his treatment left him feeling fatigued and isolated. This case study explores how medical cannabis was integrated into Peter’s care plan to manage his symptoms and help him regain his social and community life. Each case study, worth 1 CPD point, delves into real-world patient scenarios where medical cannabis was incorporated into treatment plans to manage symptoms and improve patient outcomes. Browse our case studies at https://lnkd.in/g34rbT8z 🌿 #medicalcannabis #healthcare #education #professionaldevelopment #CaseStudy

EXPLORE NEW MODULES ON SAGED 🔎 Hepatic Conditions and Medical Cannabis 🔎 HIV Case Study 🔎 Motor Neurone Disease Case Study We are excited to introduce three new modules that delve into the application of medical cannabis for complex conditions: 1️⃣ Hepatic Conditions: This module examines the evolving research on the use of medical cannabis in managing hepatitis, a global health crisis. Explore how cannabis may address primary and secondary symptoms, potentially improving quality of life for those affected. 2️⃣ HIV Case Study: Follow Peter, a 45-year-old with HIV, as we explore the integration of medical cannabis into his treatment plan to alleviate anxiety and insomnia, helping him regain his social and community life. 3️⃣ Motor Neurone Disease Case Study: Discover Nickolas' journey with motor neurone disease (MND) and how medical cannabis was utilised to manage his pain, stress, and psychological well-being, enhancing his mobility and quality of life. These modules provide valuable insights for healthcare professionals seeking to understand the therapeutic potential of medical cannabis in diverse clinical scenarios. Learn more at www.saged.com.au 🌿

Explore how medical cannabis may support the management of symptoms in conditions often under-recognised in assigned female at birth and intersex individuals. Accredited for 4 Group 1 CPD points and 8 Group 2 CPD points with the Australian Pharmacy Council (APC), this course offers pharmacists research-driven insights into the use of medical cannabis for symptom management in cases like endometriosis, PCOS, PMDD, and postpartum depression. Enhance your practice with targeted, evidence-based knowledge to better serve your patients. Enrol now at www.saged.com.au 🌿 #PharmacistEducation #MedicalCannabis

Healthcare practitioners are pivotal in providing accurate patient guidance. A deep understanding of medical cannabis is essential for informed care. Enhance your expertise by exploring our educational resources — designed for doctors, nurses and pharmacists. Visit www.saged.com.au 🌿 #medicalcannabiseducation #professionaldevelopment #healthcare

Learn how medical cannabis may help manage symptoms of conditions often under-recognised in assigned female at birth and intersex individuals. Accredited for 5.5 CPD points with APNA, this course provides nurses with research-driven insights into medical cannabis for symptom relief in cases like endometriosis, PCOS, PMDD, and postpartum depression. Strengthen your practice with focussed, evidence-based knowledge to enhance patient care. Enrol now at https://lnkd.in/gcdxaxSd 🌿

Currently, 2-5% of pregnant individuals in Australia, Canada, and parts of the USA use cannabis, with higher rates among those aged 18-25. Despite its growing use, cannabis consumption during pregnancy and chest-feeding can pose risks to the foetus or infant. → Early cannabis exposure can interfere with reproductive functions, affecting fertility, fetal development, and hormone regulation. → THC easily crosses the placenta, potentially disrupting fetal brain development and leading to long-term neurodevelopmental issues. → Cannabis use can impair parental mood, cognition, and behavior, reducing caregiving ability and impacting the child's development. Educating patients on these risks is crucial for informed decision-making. Explore this topic further in our CPD-accredited course, Medical Cannabis and Conditions Affecting Assigned Female At Birth and Intersex People. Enrol today at www.saged.com.au 🌿 References: 1. Therapeutic Goods Administration. “Guidance for the Use of Medicinal Cannabis in Australia: Overview.” Therapeutic Goods Administration (TGA), Dec. 2017, https://lnkd.in/g-b2JdE7. 2. Grzeskowiak, Luke E., et al. “The Deleterious Effects of Cannabis during Pregnancy on Neonatal Outcomes.” The Medical Journal of Australia, vol. 212, no. 11, June 2020, pp. 519–24, https://lnkd.in/gXq9e8jK. 3. Wu, C. S., Jew, C. P., & Lu, H. C. (2011). Lasting Impacts of Prenatal Cannabis Exposure and the Role of Endogenous Cannabinoids In the Developing Brain. Future Neurology, 6(4), 459–480. https://lnkd.in/gs3xy4UX 4. The Royal Women’s Hospital. Cannabis (Marajuana, Weed, Dope). Aug. 2018, pp. 1–3, https://lnkd.in/gxga2S64.

With medical cannabis emerging as a promising alternative treatment pathway, this course offers evidence-based insights into its potential for managing symptoms of: • Endometriosis • Dysmenorrhoea • Polycystic Ovary Syndrome (PCOS) • Premenstrual Dysphoric Disorder (PMDD) • Postpartum Depression (PPD) • Breast, ovarian, and uterine cancers • Perimenopause and menopause Additionally, it covers critical pregnancy-related contraindications for medical cannabis. Accredited by RACGP and ACRRM and designed for doctors, this new release CPD course will help you stay at the forefront of medical advancements, integrating both traditional and cannabis-based approaches to enhance patient outcomes. Enrol at https://lnkd.in/gx3pJriE 🌿

We're dedicated to empowering healthcare professionals with the latest insights and education on medical cannabis. Our evidence-based modules and courses are designed to help you stay informed, make informed decisions, and provide the best care for your patients. Join our community of healthcare practitioners who are committed to advancing their understanding and expertise. Explore our catalogue at www.saged.com.au 🌿

In other serotonin-affected depressive conditions, medical cannabis’ serotonin-boosting effects (1,2) have lead to a reduction in depressive symptoms (2,3) and an improvement in mood, anxiety, sleep, appetite, nausea and vomiting (2). By increasing serotonin levels, medical cannabis may relieve mood-related symptoms and anxiety linked to PCOS. To learn more about this topic, enrol in our latest CPD accredited course, "Medical Cannabis and Conditions Affecting Assigned Female at Birth and Intersex People". Accredited by RACGP, ACRRM, APNA and APC. Enrol at www.saged.com.au 🌿 References: 1. Martin, Erin L., et al. “Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial.” Frontiers in Psychiatry, vol. 12, Sept. 2021, https://lnkd.in/gMbn4CqW. 2. Ayisire, Oghenetega E., et al. “The Use of Cannabis and Its Effects on Postpartum Depression.” Cureus, vol. 14, no. 8, Aug. 2022, https://lnkd.in/gHGi8Sdm. 3. Lintzeris, Nicholas, et al. “Medical Cannabis Use in the Australian Community Following Introduction of Legal Access: The 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18).” Harm Reduction Journal, vol. 17, no. 1, June 2020, https://lnkd.in/gSgrJbdH.